Fitzgerald Clinical Research understands the importance of bringing new drugs and medical devices to the market for the people who need them. We’ve served as a trusted partner in phase two and three clinical development, where we leverage our strategic vision and execute studies quickly, safely and cost-effectively.
We seek to understand development options in the context of scientific and regulatory risks and timelines to meet your objectives. We work collaboratively as an extension of your team, with utmost integrity, transparency, and a commitment to proactively meeting challenges. We are experienced with niche treatments, mainstream pharmaceuticals, medical devices and biosimilar treatments.
Founder, Nancy Fitzgerald
Our principal, Nancy Fitzgerald, holds a masters degree in biostatistics and an MBA in company organization and management. She possesses more than 20 years experience in clinical research, fulfilling roles such as lead biostatistician, Director of Project management and most recently CEO of QST Consultations Ltd.
Prior to starting Fitzgerald Clinical Research, Nancy designed and managed project execution resulting in more than 35 NDA, ANDA, 501(k), and PMA approvals under her leadership.
Our work culture is designed to foster excellence in a flexible, creative and efficient manner.